Ezn2208
TīmeklisAdministration of EZN-2208 results in prolonged exposure to SN38. Stable disease, sometimes prolonged, was observed as best response. Conclusions: EZN-2208 has … TīmeklisEZN-2208 (PEG-SN38) is a polymeric prodrug of anticancer agent SN38 (7-ethyl-10-hydroxyl-camptothecin) which is prepared by coupling a 40 kDa, 4-arm polyethylene glycol (PEG) with SN38, through a glycine spacer. The coupling strategy was developed to selectively link the 20-OH group of SN38, thus stabilizing the E-ring of SN38 in the …
Ezn2208
Did you know?
TīmeklisEZN-2208 is a soluble derivative of SN-38, which is an active metabolite of irinotecan (158).EZN-2208 could inhibit the expression of HIF-1a mRNA and protein, which is … TīmeklisHere, we tested the pegylated SN38 compound EZN-2208 as a novel approach to treat BRCA1-mutated tumors that express ABCG2. We found that EZN-2208 therapy …
Tīmeklis2009. gada 30. jūn. · EZN-2208 will be administered by i.v. infusion weekly for 3 weeks in 4-week cycles. The cetuximab infusion will be administered before the EZN-2208 … TīmeklisProduct Description. Firtecan pegol, also known as EZN-2208,Pegylated SN-38, or PEG-SN38, is a water-soluble polyethyleneglycol-SN38 conjugate. In vitro, the IC50 of EZN-2208 ranged from 3-24 nM, which was 30- to 45-fold lower than CPT-11 or 2.5- to 3.5-fold higher than SN38. In both an early-disease Raji model and an advanced …
TīmeklisEZN-2208 treatment always resulted in lack of tumor detection at the end of trials whereas only small therapeutic effects were observed with CPT-11, as assessed by luciferase assay or tumor size, or even by staining histologic sections of tumors with antibodies recognizing neuroblastoma cells and cell proliferation. In a neuroblastoma … Tīmeklis2007. gada 23. aug. · 一项 I 期、多中心、开放标签、剂量递增研究，评估晚期实体瘤或淋巴瘤患者每 3 周静脉注射 EZN-2208 (PEG-SN38) 的安全性和耐受性 (EZN-2208-01) 这项临床研究的目的是找到可以给予晚期癌症或淋巴瘤患者的最高耐受剂量 EZN-2208。. 还将研究研究药物的安全性及其对 ...
Tīmeklis[0007] 基于上述原因，近年来人们通过在7-乙基-10-羟基喜树碱上连接亲水性基团开 发了一系列7-乙基-10-羟基喜树碱的高分子偶联物来克服其水溶性问题，而且可以避开 像伊立替康那样需要体内酶解才能释放药物的路径。如Enzon Pharmaceuticals开发的 EZN-2208高分子药物。
Tīmeklis2012. gada 20. maijs · 1017 Background: EZN-2208 is a water-soluble PEGylated conjugate of SN38. EZN-2208 results in prolonged exposure of tumors to SN38 via preferential accumulation of EZN-2208 in the tumor and prolonged release of SN38. These data represent the final analysis of our study evaluating EZN-2208 in MBC. … roman empire truckingTīmeklisNanoparticle size. It is currently thought that the diameter of nanoparticle therapeutics for cancer should be in the range of 10-100 nm. The lower bound is based on the measurement of sieving coefficients for the glomerular capillary wall, as it is estimated that the threshold for first-pass elimination by the kidneys is 10 nm (diameter) (1). roman empire theos hypsistosTīmeklisEfficacy of EZN-2208 in APL was measured in vitro by assessing expression of HIF-1α target genes, cell migration, clonogenicity, and differentiation, vis a vis the cytotoxic and cytostatic effects of this compound. In vivo, EZN-2208 was used in mouse models of APL driven by PML-RARα or PLZF-RARα, either alone or in combination with ATRA. roman empire schismTīmeklis2013. gada 15. dec. · EZN-2208 was a PEG-conjugated SN-38, which couples a branched PEG moiety to the lactone ring of SN-38 and stabilized the lactone ring, but its linkage chemistry appeared to have about 12-minute ... roman empire then and now mapTīmeklis研究发现肿瘤细胞通过各种机制诱导缺氧，例如高新陈代谢速率和高氧消耗，从而引起内皮功能障碍或由于对血管的各种作用而破坏氧气的输送，制造慢性缺氧环境，激活低氧诱导因子HIF（Hypoxia-inducible factors）信号通路，加速肿瘤的生长，提高肿瘤的侵袭性 ... roman empire summary for kidshttp://enzon.com/docs/development_overview roman empire vs han chinaTīmeklis2024. gada 10. maijs · EZN2208, which is in a Phase I trial, has a four-arm polyethylene glycol (PEG) conjugation at the C20 position of SN38 to increase water-solubility and decrease diarrhea, although neutropenia has also occurred in patients. 11 NK012, now in a Phase II study, has hydrophilic PEG bound via a hydrophobic polyglutamate … roman empire republican government